Skip to main content
. Author manuscript; available in PMC: 2024 Dec 1.
Published in final edited form as: Pediatr Blood Cancer. 2023 Oct 2;70(12):e30701. doi: 10.1002/pbc.30701

TABLE 1.

Baseline patient and tumor characteristics

Bone Marrow Metastatic

Variable Number (%)

Total Number Patients 179 100

Age median, range 14.8 (0.02, 26.3)

Sex

 Male 103 57.5

 Female 76 42.5

Age at diagnosis, years

 < 1 3 1.7

 1 – 9 47 26.3

 ≥ 10 129 72.1

Race

 Nonwhite 29 16.2

 White 132 73.7

Unknown 18 10.1

Histology Subtype

 Alveolar 136 76.0

  Alveolar Fusion Status
   Positive FOXO1 Fusion 68 50.0
    PAX3-FOXO1 47 69.1
    PAX7-FOXO1 5 7.4
    Unknown Partner-FOXO1 16 23.5
   Negative FOXO1 Fusion 3 2.2
   Unknown Fusion Status 65 47.8

 Embryonal 25 14.1

 Spindle cell 1 0.6

 Other 17 9.5

Primary Site

 Extremity 57 31.8

 Retroperitoneal 25 14.0

 Trunk/paravertebral 18 10.1

 Bladder/Prostate 15 8.4

 Parameningeal 14 7.8

 Perineum 13 7.3

 GU non-Bladder/Prostate 12 6.7

 Other 9 5.0

 Head and Neck, Non-Parameningeal 7 3.9

Unknown 7 3.9

Intrathoracic 1 0.6

Orbit 1 0.6

Tumor Invasiveness

 T1 11 6.2

 T2 167 93.3

Unknown 1 0.6

Tumor Size, cm

 ≤ 5 51 28.5

 >5 128 71.5

Regional Lymph Node

 N0 51 28.5

 N1 118 65.9

 Nx 10 5.6

Number of Metastatic Sites

  1 – Bone marrow Only 22 12.3

  2 46 25.7

  ≥ 3 110 61.5

  missing 1 0.6

Additional Metastatic Sites

 Bone 100 55.9

 Lung 70 39.1

 Lymph node 81 45.3

Oberlin Score

  1 10 5.6

  2 34 19.0

  3 65 36.3

  4 63 35.2

  Missing/Not calculable 7 3.9